These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 34420582)

  • 41. Hepatitis C treatment: an incipient therapeutic revolution.
    deLemos AS; Chung RT
    Trends Mol Med; 2014 Jun; 20(6):315-21. PubMed ID: 24636306
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Constitutive expression of 25-hydroxyvitamin D3-1alpha-hydroxylase in a transformed human proximal tubule cell line: evidence for direct regulation of vitamin D metabolism by calcium.
    Bland R; Walker EA; Hughes SV; Stewart PM; Hewison M
    Endocrinology; 1999 May; 140(5):2027-34. PubMed ID: 10218951
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Vitamin D pathway gene polymorphisms and hepatocellular carcinoma in chronic hepatitis C-affected patients treated with new drugs.
    Cusato J; Boglione L; De Nicolò A; Favata F; Ariaudo A; Mornese Pinna S; Guido F; Avataneo V; Cantù M; Carcieri C; Cariti G; Di Perri G; D'Avolio A
    Cancer Chemother Pharmacol; 2018 Mar; 81(3):615-620. PubMed ID: 29356898
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Hepatitis C and Treatment in Patients with Chronic Kidney Disease.
    Jalota A; Lindner BK; Thomas B; Lerma EV
    Dis Mon; 2021 Feb; 67(2):101017. PubMed ID: 32553421
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Present, old and future strategies for anti-HCV treatment in patients infected by genotype-1: estimation of the drug costs in the Calabria Region in the era of the directly acting antivirals.
    Strazzulla A; Costa C; Pisani V; De Maria V; Giancotti F; Di Salvo S; Parisi SG; Basso M; Franzetti MM; Marascio N; Liberto MC; Barreca GS; Lamberti AG; Zicca E; Postorino MC; Matera G; Focà A; Torti C
    BMC Infect Dis; 2014; 14 Suppl 5(Suppl 5):S3. PubMed ID: 25236374
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Genetic Polymorphisms within Interferon-λ Region and Interferon-λ3 in the Human Pathophysiology: Their Contribution to Outcome, Treatment, and Prevention of Infections with Hepatotropic Viruses.
    Grzegorzewska AE
    Curr Med Chem; 2019; 26(25):4832-4851. PubMed ID: 30027841
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Serum vitamin D₃ does not correlate with liver fibrosis in chronic hepatitis C.
    Ren Y; Liu M; Zhao J; Ren F; Chen Y; Li JF; Zhang JY; Qu F; Zhang JL; Duan ZP; Zheng SJ
    World J Gastroenterol; 2015 Oct; 21(39):11152-9. PubMed ID: 26494969
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The combination of alisporivir plus an NS5A inhibitor provides additive to synergistic anti-hepatitis C virus activity without detectable cross-resistance.
    Chatterji U; Garcia-Rivera JA; Baugh J; Gawlik K; Wong KA; Zhong W; Brass CA; Naoumov NV; Gallay PA
    Antimicrob Agents Chemother; 2014 Jun; 58(6):3327-34. PubMed ID: 24687498
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Complementary role of vitamin D deficiency and the interleukin-28B rs12979860 C/T polymorphism in predicting antiviral response in chronic hepatitis C.
    Bitetto D; Fattovich G; Fabris C; Ceriani E; Falleti E; Fornasiere E; Pasino M; Ieluzzi D; Cussigh A; Cmet S; Pirisi M; Toniutto P
    Hepatology; 2011 Apr; 53(4):1118-26. PubMed ID: 21480318
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The serum vitamin D metabolome: What we know and what is still to discover.
    Tuckey RC; Cheng CYS; Slominski AT
    J Steroid Biochem Mol Biol; 2019 Feb; 186():4-21. PubMed ID: 30205156
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Hepatitis C Virus Eradication with New Interferon-Free Treatment Improves Metabolic Profile in Hepatitis C Virus-Related Liver Transplant Recipients.
    Beig J; Orr D; Harrison B; Gane E
    Liver Transpl; 2018 Aug; 24(8):1031-1039. PubMed ID: 29577581
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Disparities in Treatment with Direct-Acting Hepatitis C Virus Antivirals Persist Among Adults Coinfected with HIV and Hepatitis C Virus in US Clinics, 2010-2018.
    Simoncini GM; Hou Q; Carlson K; Buchacz K; Tedaldi E; Palella F; Durham M; Li J;
    AIDS Patient Care STDS; 2021 Oct; 35(10):392-400. PubMed ID: 34623891
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Hepatitis C virus NS5A region mutation in chronic hepatitis C genotype 1 patients who are non-responders to two or more treatments and its relationship with response to a new treatment.
    Muñoz de Rueda P; Fuentes Rodríguez JM; Quiles Pérez R; Gila Medina A; Martín Álvarez AB; Casado Ruíz J; Ruíz Extremera A; Salmerón J
    World J Gastroenterol; 2017 Jul; 23(25):4538-4547. PubMed ID: 28740342
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The role of HCV proteins on treatment outcomes.
    Kumthip K; Maneekarn N
    Virol J; 2015 Dec; 12():217. PubMed ID: 26666318
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Avasimibe: A novel hepatitis C virus inhibitor that targets the assembly of infectious viral particles.
    Hu L; Li J; Cai H; Yao W; Xiao J; Li YP; Qiu X; Xia H; Peng T
    Antiviral Res; 2017 Dec; 148():5-14. PubMed ID: 29074218
    [TBL] [Abstract][Full Text] [Related]  

  • 56. 25-Hydroxyvitamin D3, the prohormone of 1,25-dihydroxyvitamin D3, inhibits the proliferation of primary prostatic epithelial cells.
    Barreto AM; Schwartz GG; Woodruff R; Cramer SD
    Cancer Epidemiol Biomarkers Prev; 2000 Mar; 9(3):265-70. PubMed ID: 10750664
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Remission of long-term hepatic and renal disease induced by HCV after direct-acting antivirals therapy.
    Arruda RM; Batista AD; Filgueira NA; Moura IF; Sette LH; Lopes EP
    J Bras Nefrol; 2021; 43(1):117-120. PubMed ID: 33022028
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Hepatitis C: therapeutic perspectives.
    Cornberg M; Wedemeyer H; Manns MP
    Forum (Genova); 2001; 11(2):154-62. PubMed ID: 11948360
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Symbiotic chemo- and immuno-therapy for hepatitis B and C viruses.
    Agrawal B; Kumar R
    World J Gastroenterol; 2016 Jul; 22(25):5623-6. PubMed ID: 27433078
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Vitamin D pathway gene variants and HCV-2/3 therapy outcomes.
    Cusato J; Allegra S; Boglione L; De Nicolò A; Baietto L; Cariti G; Di Perri G; D'Avolio A
    Antivir Ther; 2015; 20(3):335-41. PubMed ID: 25279449
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.